Sharmin Khan

Author PubWeight™ 9.49^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.	Am J Hematol	2009	2.12
2	The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.	Blood	2009	1.08
3	Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.	Stem Cells	2011	1.07
4	Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.	J Bone Miner Res	2012	1.03
5	Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.	Am J Hematol	2013	0.95
6	Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.	PLoS One	2010	0.89
7	Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.	Cancer Lett	2009	0.84
8	Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.	Br J Haematol	2009	0.80
9	NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.	Exp Hematol	2013	0.77